计算溶液所需的质量、体积或浓度。
| 活性类型 | 活性值-log(M) | 作用机制 | 期刊 | 参考文献(PubMed IDs) |
|---|
提供 ≥99% 纯度,适用于对基线干扰要求严格的色谱和分析工作流程。
2-8°C储存,避光,干燥。低温运输 。请查阅批次 COA 获取详细规格。
SDS、COA、产品数据表及规格说明书均可下载。可通过批号查询获取批次 COA。
在色谱分析、有机合成和交叉偶联反应领域已被 0 篇同行评审文献引用。
ONO-8430506 is an orally bioavailable and potent autotaxin (ATX)/ENPP2 inhibitor with the IC 90 of 100 nM for ATX activity in mouse plasma .
In Vitro
Autotaxin, also known as ectonucleotide pyrophosphatase/phosphodiesterase 2 (ENPP2), is a secreted enzyme that has lysophospholipase D activity. The IC 50 s of ONO-8430506 for the lysophospholipase D (LysoPLD) activity of recombinant human ATX/ENPP2 are 5.1 nM in an assay using synthetic fluorescent substrate (FS-3) and 4.5 nM in an assay using a natural substrate (16:0-LPC). ONO-8430506 shows efficient inhibition of lysophosphatidic acid (LPA) formation, with IC 50 s of approximately 10 nM with both recombinant and plasma derived ATX/ENPP2 from various animal species. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
ONO-8430506 (10 mg/kg/day; gavage; for 21 days) slows initial tumor growth and limits lung metastasis . ONO-8430506 decreases the initial phase of breast tumor growth and subsequent lung metastases by ~60% in a syngeneic orthotopic mouse model . ONO-8430506 (oral; 30 mg/kg) demonstrates good pharmacokinetics and persistently inhibits plasma lysophosphatidic acid formation in rats. ONO-8430506 (30 or 100 mg/kg) enhances the antitumor effect of Paclitaxel in a breast cancer model. ONO-8430506 exhibits moderate oral bioavailability (rat 51.6%, dog 71.1%, and monkey 30.8%) and C max (rat 261, dog 1670, and monkey 63 ng/mL) following oral administration (rat 1, dog 1, and monkey 1 mg/kg). ONO-8430506 exhibits terminal elimination half-lives (rat 3.4, dog 8.9, and monkey 7.9 h) due to low plasma clearance (8.2, 4.7, and 5.8 mL/min/kg respectively) combined with large volumes of distribution (1474, 1863, and 2275 mL/kg respectively) following intravenous administration (rat 0.3, dog 0.3, and monkey 0.3 mg/kg). MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Female BALB/c mice, 8-10 wk old (BALB/cAnNCrl) Dosage: 10 mg/kg Administration: Gavaged daily for 21 days; 10 μL/g Result: Tumor growth in ONO-8430506-treated mice caught up to the vehicle group by day 13; thereafter, primary tumor size was not significantly different from the vehicle-treated mice. However, treatment with ONO-8430506 decreased the numbers of metastatic nodules in the lungs at day 21 by ~60%.
Form:Solid
分类树(Taxonomy Tree)
| 界(kingdom) | 有机化合物 |
|---|---|
| 超类(Superclass) | 脂质和脂质样分子 |
| 类(Class) | 异戊烯醇脂质 |
| 亚类(Subclass) | 单萜类化合物 |
| 中间层级节点(Intermediate Tree Nodes) | 暂无 |
| 直接上位类(Direct Parent) | 芳香单萜类化合物 |
| 其他上位类(Alternative Parents) | 吡咯并吡啶 氟苯类 取代吡咯 吡啶及其衍生物 芳基氟化物 叔羧酸酰胺 杂芳族化合物 叔胺 氨基酸 氮杂环化合物 羧酸 一元羧酸及其衍生物 羰基化合物 有机氧化物 有机氟化物 碳氢化合物衍生物 |
| 分子骨架(Molecular Framework) | 芳香族杂多环化合物 |
| 取代基(Substituents) | 氨基酸 - 氨基酸 - 氨基酸或其衍生物 - 芳香族杂多环化合物 - 芳香单萜类化合物 - 芳基氟化物 - 芳基卤化物 - 氮杂环 - 苯基化合物 - 羰基 - 羧酰胺基 - 羧酰胺基 - 羧酸衍生物 - 氟萘 - 卤苯 - 杂芳香族化合物 - 烃衍生物 - 单羧酸或其衍生物 - 单环苯基基团 - 有机硝基化合物 - 有机氧化物 - 有机氧化合物 - 有机氟化物 - 有机卤化物 - 有机杂环化合物 - 有机氮化合物 - 有机氧化合物 - 吡啶 - 吡咯 - 吡咯吡嗪 - 取代吡咯 - 三芳基胺 - 叔羧酸酰胺 |
| 描述(Description) | 该化合物属于芳香单萜类有机化合物。这类化合物至少含一个芳香环。 |
| 外部描述符(External Descriptors) | 暂无 |
| 作用机制 | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | 参考文献 |
|---|